EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, GT Biopharma's enterprise value is $-3.63 Mil.
GT Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, GT Biopharma's EV-to-Revenue for today is .
The historical rank and industry rank for GT Biopharma's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of GT Biopharma was 1025099.57. The lowest was 524.00. And the median was 1375.91.
GTBP's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.69 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-06-23), GT Biopharma's stock price is $2.85.
GT Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, GT Biopharma's PS Ratio for today is .
GT Biopharma EV-to-Revenue Historical Data
The historical data trend for GT Biopharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of GT Biopharma's EV-to-Revenue
For the Biotechnology subindustry, GT Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GT Biopharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GT Biopharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where GT Biopharma's EV-to-Revenue falls into.
GT Biopharma's current Enterprise Value is $-3.63 Mil.
GT Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GT Biopharma's share price for today is $2.85.
GT Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GT Biopharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of GT Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GTBP has been successfully added to your 